PRODUCT INFORMATION

NAME OF THE MEDICINE

Active ingredient: Carbamazepine.

Chemical name: 5H-dibenz(b,f)azepine-5-carboxamide

Structural formula:

![Structural formula of Carbamazepine]

Molecular formula: C_{15}H_{12}N_{2}O  
Molecular weight: 236.3

CAS number: 298-46-4

DESCRIPTION

Carbamazepine is a white or yellowish-white, crystalline powder; almost odourless; tasteless or with a slightly bitter taste. It has a melting point of 189°-193°C. Carbamazepine is practically insoluble in water and in ether, sparingly soluble in ethanol (96%), and soluble in 10 parts of chloroform.

Each Teril tablet contains 200 mg of carbamazepine and the following inactive excipients: microcrystalline cellulose, pregelatinised maize starch, colloidal anhydrous silica, purified talc, sodium starch glycollate and magnesium stearate.

PHARMACOLOGY

Carbamazepine is an antiepileptic, neurotropic and psychotropic agent.

Pharmacodynamics

Carbamazepine as an antiepileptic agent has been shown to be effective in the treatment of partial seizures (simple and complex) with and without secondary generalisation, generalised tonic-clonic seizures (grand mal) and combinations of these seizure types.

In some clinical studies, carbamazepine (given as monotherapy to patients with epilepsy, including children and adolescents) has been reported to exert a mild psychotropic action, including a beneficial effect on attentiveness, cognitive performance and symptoms of anxiety and depression, as well as a decrease in irritability and aggressiveness. Other studies have not confirmed these findings.
As a neurotropic agent, carbamazepine is clinically effective in relieving paroxysmal attacks of pain in idiopathic trigeminal neuralgia.

As a psychotropic agent, carbamazepine has shown clinical efficacy as treatment for mania as well as for the maintenance treatment of bipolar affective disorders, when given either as monotherapy or in combination with neuroleptics, antidepressants or lithium.

The mechanism of action of carbamazepine has been partially elucidated. Carbamazepine stabilises hyperexcited nerve membranes, inhibits repetitive neuronal discharges and reduces synaptic propagation of excitatory impulses.

It is conceivable that prevention of repetitive firing of sodium-dependent action potentials in depolarised neurons via use- and voltage-dependent blockade of sodium channels may be the main mechanism of action of carbamazepine.

Whereas reduction of glutamate release and stabilization of neuronal membranes may account mainly for the antiepileptic effects, it is speculated that the depressant effect on dopamine and noradrenaline turnover could be responsible for the antimanic properties of carbamazepine.

Carbamazepine possesses anticholinergic and antidiuretic activity and may suppress ventricular automaticity through its membrane depressant effect.

**Pharmacokinetics**

**Absorption**

Carbamazepine is relatively slowly but almost completely absorbed from the gastrointestinal tract.

*Plasma concentrations.* When taken as a single oral dose, a peak concentration of unchanged carbamazepine is reached within 4 to 24 hours (majority within 12 hours). During one study, the peak following the oral administration of 400 mg was approximately 4.5 microgram/mL.

Steady state is generally achieved within about one to two weeks depending individually upon auto-induction by carbamazepine and hetero-induction by other enzyme inducing drugs, as well as pre-treatment status, dosage and duration of treatment. The therapeutic range of steady state is carbamazepine 4 to 12 microgram/mL (17 to 50 micromol/L). The main metabolite, carbamazepine-10,11-epoxide, possesses anticonvulsant activity and reaches concentrations approximately 30% of those of carbamazepine.

*Bioavailability.* Absolute bioavailability could not be determined, as an intravenous formulation was not developed. Nevertheless, it appears that systemic availability approaches 100% and is unaffected by food.

*Serum protein binding.* 70 to 80%. The concentration of unchanged substance in saliva and cerebrospinal fluid (CSF) reflects the nonprotein bound fraction present in plasma.

**Distribution**

The concentration of unchanged drug in the CSF and saliva is approximately 20 to 30% of that attained in plasma. Breast milk concentration ranges from 25 to 60% of the plasma concentration. Carbamazepine readily crosses the placenta. The apparent volume of distribution was found to be 0.8 to 1.9 L/kg.
Metabolism

Carbamazepine is metabolised in the liver via the epoxide-diol pathway. The main metabolite, carbamazepine-10,11-epoxide, is pharmacologically active. Cytochrome P450 3A4 has been identified as the major isoform responsible for the formation of carbamazepine-10, 11-epoxide itself. Human microsomal epoxide hydrolase has been identified as the enzyme responsible for the 10,11-transdiol derivative from carbamazepine-10,11 epoxide. Carbamazepine is capable of inducing its own metabolism by the hepatic monooxygenase system.

Excretion

The elimination half-life of unchanged carbamazepine following a single oral dose averaged 36 hours whereas after repeated administration, which leads to hepatic enzyme induction, it averaged 16 to 24 hours depending on the duration of treatment. In patients receiving concomitant treatment with other liver enzyme inducing drugs (e.g. phenytoin, phenobarbitone), half-life values averaging 9 to 10 hours have been found. The mean elimination half-life of the 10, 11-epoxide metabolite in the plasma is about six hours following single oral doses of the epoxide itself. Following a single 400 mg dose, 72% was excreted in the urine mainly in the form of epoxidated, hydroxylated and conjugated metabolites. Some 28% of the dose was excreted in the faeces.

Note. Kinetics were not altered in the elderly; there are no data on patients with impaired hepatic or renal function.

INDICATIONS

Epilepsy

- Partial seizures with complex or simple symptomatology (with or without loss of consciousness), with or without secondary generalisation.
- Generalised seizures with a tonic-clonic component.
- Mixed seizure patterns incorporating the above.

Teril is suitable for monotherapy and combination therapy. Teril is usually not effective in absence seizures, atonic seizures or myoclonic seizures and should not be used for status epilepticus (see PRECAUTIONS).

Idiopathic trigeminal neuralgia

For the relief of pain in idiopathic trigeminal neuralgia, trigeminal neuralgia due to multiple sclerosis, and idiopathic glossopharyngeal neuralgia. (Carbamazepine is not a simple analgesic and is not intended for trivial facial pain or headache.)

Mania and bipolar affective disorders

Treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.
CONTRAINDICATIONS

- Known hypersensitivity to carbamazepine or structurally related drugs (e.g. tricyclic antidepressants) or to any other component of the formulation
- Atrioventricular block
- Systemic lupus erythematosus
- History of hepatic porphyrias (e.g. acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda)
- History of bone marrow depression.
- Because it is structurally related to tricyclic antidepressants, Teril is not recommended in combination with monoamine oxidase inhibitors (MAOIs). Before administering Teril, MAOIs should be discontinued for a minimum of 2 weeks, or longer if the clinical situation permits.
- Hepatic failure (as metabolism occurs in the liver, it is recommended that carbamazepine not be given to patients with significant hepatic dysfunction).

PRECAUTIONS

Teril should be given only under medical supervision. Teril should be prescribed only after a critical benefit-risk appraisal and under close monitoring in patients with a history of cardiac, hepatic or renal damage, adverse haematological reactions to other drugs, or interrupted courses of therapy with Teril.

Suicidal Behaviour and Ideation

Antiepileptic drugs (AEDs), including carbamazepine, increase the risk of suicidal thoughts or behaviour in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behaviour, and/or any unusual changes in mood or behaviour.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomised to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behaviour compared to patients randomised to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behaviour or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behaviour for every 530 patients treated.

There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.
The increased risk of suicidal thoughts or behaviour with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behaviour beyond 24 weeks could not be assessed.

The risk of suicidal thoughts or behaviour was generally consistent among drugs in the data analysed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analysed. Table 1 shows absolute and relative risk by indication for all evaluated AEDs.

<table>
<thead>
<tr>
<th>Indication</th>
<th>Placebo patients with events / 1000 patients</th>
<th>Drug patients with events / 1000 patients</th>
<th>Relative Risk: Incidence of events in Drug patients/ Incidence in Placebo patients</th>
<th>Risk Difference: Additional Drug patients with events per 1000 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epilepsy</td>
<td>1.0</td>
<td>3.4</td>
<td>3.5</td>
<td>2.4</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>5.7</td>
<td>8.5</td>
<td>1.5</td>
<td>2.9</td>
</tr>
<tr>
<td>Other</td>
<td>1.0</td>
<td>1.8</td>
<td>1.9</td>
<td>0.9</td>
</tr>
<tr>
<td>Total</td>
<td>2.4</td>
<td>4.3</td>
<td>1.8</td>
<td>1.9</td>
</tr>
</tbody>
</table>

The relative risk for suicidal thoughts or behaviour was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing carbamazepine or any other AED must balance this risk with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behaviour. Should suicidal thoughts and behaviour emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behaviour and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behaviour, or the emergence of suicidal thoughts, behaviour, or thoughts about self-harm. Behaviours of concern should be reported immediately to the treating doctor.

**Hypersensitivity**

Teril may trigger hypersensitivity reactions, including multi-organ hypersensitivity reactions, which can affect the skin, liver, haematopoietic organs and lymphatic system or other organs, either individually or together in the context of a systemic reaction (see **ADVERSE EFFECTS**).

The HLA-A*3101 allele has been found to be associated with the occurrence of hypersensitivity syndrome, including maculopapular rash.
Patients who have exhibited hypersensitivity reactions to carbamazepine should be informed that approximately 25 to 30% of these patients may experience hypersensitivity reactions with Oxcarbazepine (Trileptal). Cross-hypersensitivity can occur between carbamazepine and phenytoin.

In general, if signs and symptoms suggestive of hypersensitivity reactions occur, Teril should be withdrawn immediately.

Seizures

Teril should be used with caution in patients with a mixed seizure disorder including typical and atypical absence seizures. In all of these conditions carbamazepine may exacerbate seizures. In case of exacerbation of seizures, Teril should be discontinued.

Hepatic Function

Baseline and periodic evaluations of hepatic function must be performed during treatment with Teril, particularly in patients with a history of hepatic disease and in elderly patients. The drug should be withdrawn immediately in cases of aggravated hepatic dysfunction or active hepatic disease.

Renal Function

Baseline and periodic complete urinalysis and BUN determinations are recommended.

Haematological effects

Aplastic anaemia and agranulocytosis (in some cases fatal) have been reported in association with the use of carbamazepine. However, due to the very low incidence of these diseases, meaningful risk estimates for carbamazepine are difficult to obtain. The overall risk in the general untreated population has been estimated at 4.7 persons per million per year for agranulocytosis and 2 persons per million per year for aplastic anaemia.

Although reports of transient or persistent reductions in platelet count or white cell count are not uncommon in association with the use of carbamazepine, data are not available to estimate accurately their incidence or outcome. Nevertheless, the vast majority of leucopenia cases have not progressed to aplastic anaemia or agranulocytosis. Nonetheless, complete blood counts, including platelets and possibly reticulocytes and serum iron, should be obtained before treatment, as a baseline and periodically thereafter.

If during treatment definitely low or decreased white blood cell or platelet counts are observed, the patient and the complete blood count should be monitored closely. Teril should be discontinued if any evidence of significant bone marrow depression appears.

Because the onset of potentially serious blood dyscrasias may be rapid, patients should be made aware of early toxic signs and symptoms of a potential haematological problem, as well as symptoms of dermatological or hepatic reactions. If reactions such as fever, sore throat, rash, ulcers in the mouth, easy bruising, petechial or purpuric haemorrhage appear, the patient should be advised to consult their physician immediately.
Serious dermatological reactions

Serious dermatologic reactions, including toxic epidermal necrolysis (TEN: also known as Lyell’s syndrome) and Stevens-Johnson syndrome (SJS), have been reported very rarely with Teril. Patients with serious dermatological reactions may require hospitalization, as these conditions may be life-threatening and may be fatal. Most of the SJS/TEN cases appear in the first few months of treatment with Teril. If signs and symptoms suggestive of severe skin reactions (e.g. SJS/TEN) appear, Teril should be withdrawn at once and alternative therapy should be considered.

There is growing evidence of the role of different HLA alleles in predisposing patients to immune-mediated adverse reactions.

Association with HLA-A*3101

Human Leukocyte Antigen (HLA)-A*3101 may be a risk factor for the development of cutaneous adverse drug reactions such as SJS, TEN, DRESS, AGEP and maculopapular rash. Retrospective genome-wide studies in Japanese and Northern European populations reported association between severe skin reactions (SJS, TEN, DRESS, AGEP and maculopapular rash) associated with carbamazepine use and the presence of the HLA-A*3101 allele in these patients.

Testing for the presence of HLA-A*3101 allele should be considered in patients with ancestry in genetically at-risk populations (for example, patients of the Japanese and Caucasian populations, patients who belong to the indigenous populations of the Americas, Hispanic populations, people of southern India, and people of Arabic descent), prior to initiating treatment with carbamazepine. The use of carbamazepine should be avoided in patients who are found to be positive for HLA-A*3101, unless the benefits clearly outweigh the risks. Screening is generally not recommended for any current carbamazepine users, as the risk of SJS/TEN, AGEP, DRESS and maculopapular rash is largely confined to the first few months of therapy, regardless of HLA-A*3101 status.

Association with HLA-B*1502

Retrospective studies in patients of Han Chinese ancestry found a strong correlation between SJS/TEN skin reactions associated with carbamazepine and the presence in these patients of the Human Leukocyte Antigene (HLA)-B*1502 allele. Higher reporting rates of SJS (rare rather than very rare) are reported in some countries in Asia (e.g. Taiwan, Malaysia and thePhilippines) in which there is a higher prevalence of the HLA-B*1502 allele in the population. The prevalence of carriers of this allele in Asian populations is above 15% in the Philippines, Thailand, Hong Kong and Malaysia, around 10% in Taiwan, around 4% in North China, around 2 to 4% in South Asia including Indians, and less than 1% in Japan and Korea. The prevalence of the HLA-B*1502 allele is negligible in Caucasian, African, indigenous peoples of the Americas, and Hispanic populations sampled.

Testing for the presence of HLA-B*1502 allele should be considered in patients with ancestry in genetically at-risk populations, prior to initiating treatment with carbamazepine. If testing for the presence of the HLA-B*1502 allele should be performed, high-resolution “HLA-B*1502 genotyping” is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected and negative if no HLA-B*1502 alleles are detected.
The use of carbamazepine should be avoided in tested patients who are found to be positive for HLA-B*1502 unless the benefits clearly outweigh the risks. Screening is not generally recommended in patients from populations in which the prevalence of HLA-B*1502 is low. Screening is generally not recommended for any current carbamazepine users, as the risk of SJS/TEN is largely confined to the first few months of therapy, regardless of HLA-B*1502 status.

The identification of subjects carrying the HLA-B*1502 allele and the avoidance of carbamazepine therapy in these subjects has been shown to decrease the incidence of carbamazepine-induced SJS/TEN.

Limitation of genetic screening

Genetic screening results must never substitute for appropriate clinical vigilance and patient management. Many Asian patients positive for HLA-B*1502 and treated with carbamazepine will not develop SJS/TEN and patients negative for HLA-B*1502 of any ethnicity can still develop SJS/TEN. Similarly many patients positive for HLA-A*3101 and treated with carbamazepine will not develop SJS, TEN, DRESS, AGEP or maculopapular rash and patients negative for HLA-A*3101 of any ethnicity can still develop these severe cutaneous adverse reactions. The role of other possible factors in the development of, and morbidity from these severe cutaneous adverse reactions, such as AED dose, compliance, concomitant medications, co-morbidities, and the level of dermatologic monitoring have not been studied.

Other dermatologic reactions

Mild skin reactions, e.g. isolated macular or maculopapular exanthemata, can also occur and are mostly transient and not hazardous, and they usually disappear within a few days or weeks, either during the course of treatment or following a decrease in dosage. However, since it may be difficult to differentiate the early signs of more serious skin reactions from mild transient reactions, the patient should be kept under close surveillance with consideration given to immediately withdrawing the drug should the reactions worsen with continued use.

The HLA-A*3101 allele has been found to be associated with less severe adverse cutaneous reactions from carbamazepine and may predict the risk of these reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption). However, the HLA-B*1502 allele has not been found to predict the risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption).

Anticholinergic effects

Teril has shown mild anticholinergic activity; patients with increased intraocular pressure or prostatism should, therefore, be observed closely during therapy (see ADVERSE EFFECTS).

Ophthalmological effects

Carbamazepine therapy has been associated with punctate cortical lens opacities and conjunctivitis although a direct causal relationship has not been established. Baseline and periodic ophthalmological examinations are recommended.
Psychiatric effects

The possibility of activation of a latent psychosis and, in elderly patients, of confusion or agitation should be borne in mind.

Endocrinological effects

There have very rare been reports of impaired male fertility and/or abnormal spermatogenesis.

Breakthrough bleeding has been reported in women taking Teril while using hormonal contraceptives. The reliability of hormonal contraceptives may be adversely affected by Teril (see INTERACTIONS WITH OTHER MEDICINES). Due to enzyme induction, Teril may cause failure of the therapeutic effect of any drugs containing oestrogen and/or progesterone (e.g., failure of contraception) (see INTERACTIONS WITH OTHER MEDICINES). Women of childbearing age should be advised to consider using alternate forms of birth control while taking Teril.

Monitoring of plasma concentrations

Although correlations between dosage and plasma concentrations of carbamazepine, and between plasma concentrations and clinical efficacy or tolerability are rather tenuous, monitoring of the plasma concentrations may be useful in the following circumstances: dramatic increase in seizure frequency; verification of patient compliance; during pregnancy; when treating children or adolescents; in suspected absorption disorders; in suspected toxicity when more than one drug is being used (see INTERACTIONS WITH OTHER MEDICINES).

Dose reduction or withdrawal

Abrupt dose reduction or withdrawal may precipitate convulsions or even status epilepticus. If treatment with Teril has to be withdrawn abruptly in a patient with epilepsy, the changeover to the new antiepileptic compound should be made under cover of a suitable drug (e.g. intravenous diazepam or intravenous phenytoin).

Effects on ability to drive or use machines

The patient's ability to react may be impaired by dizziness and drowsiness caused by carbamazepine, especially at the start of treatment or in association with dose adjustments; patients should therefore exercise due caution when driving a vehicle or operating machinery.

Carcinogenesis, mutagenesis, impairment of fertility

In rats treated with oral carbamazepine for 2 years at doses of 25, 75 and 250 mg/kg/day, the incidence of hepatocellular tumours was found to be dose dependently increased in females, and aspermatogenesis and testicular atrophy were observed at all doses. This dose range is 0.2 to 2 times the maximum recommended clinical dose of 1200 mg/day, on a surface area basis. The significance of these carcinogenicity findings relative to the use of carbamazepine in humans is not known. There have very rare been reports of impaired male fertility and/or abnormal spermatogenesis.

Bacterial and mammalian mutagenicity studies yielded negative results.
Use in Pregnancy (Category D)

In animals (mice, rats, rabbits), oral administration of carbamazepine during organogenesis led to increased embryonic mortality at daily doses which caused maternal toxicity (above 200 mg/kg/day, or about 1.5 times the maximum recommended clinical dose on a surface area basis). In the rat, there was also some indication of abortion at 300 mg/kg/day. Near term rat foetuses showed growth retardation, again at maternally toxic doses. In mice, carbamazepine (40 to 240 mg/kg/day, orally; less than the maximum recommended clinical dose on a surface area basis) caused defects (mainly dilatation of cerebral ventricles) in 4.7% of exposed foetuses as compared with 1.3% in controls. In rats, a small number of congenital abnormalities occurred following oral carbamazepine doses at 250 and 650 mg/kg (respectively, 2 and 4 times the maximum recommended clinical dose on a surface area basis).

The risk of having an abnormal child as a result of medication is far outweighed by the dangers to the mother and foetus of uncontrolled epilepsy. The risk of a mother with epilepsy and taking anticonvulsants giving birth to a baby with an abnormality is about three times that of the general population. Some of this risk is due to the anticonvulsant drugs taken. Although carbamazepine has been known to produce malformations in one animal species (the rat), the significance of this in humans is not known. Mothers taking more than one anticonvulsant drug have a higher risk of having a baby with a malformation than mothers taking one drug. Overall, the risk of having an abnormal child as a result of medication is far outweighed by the dangers to the mother and foetus of uncontrolled epilepsy.

Folic acid deficiency is known to occur in pregnancy and anti-epileptic drugs may aggravate the deficiency. This deficiency may contribute to the increased incidence of birth defects in the offspring of treated epileptic women. Folic acid supplementation has, therefore, been recommended before and during pregnancy. Folic acid supplementation (5 mg daily) should be commenced four weeks prior to and continue for twelve weeks after conception.

Review of a cohort of 1457 women exposed to carbamazepine not combined with valproate revealed a 1% incidence of spina bifida. A smaller cohort of 50 women on carbamazepine monotherapy produced two babies with spina bifida. Other congenital anomalies such as craniofacial defects, cardiovascular malformations, hypospadias and anomalies involving various body systems (e.g. fingernail hypoplasia and developmental disorder) have been reported. There is evidence suggestive of an increased risk of malformations in humans when carbamazepine has been used in combination with other anticonvulsant drugs. Monotherapy is recommended wherever possible. Patients should be counselled regarding the possibility of an increased risk of malformations and specialist prenatal diagnosis including detailed mid-trimester ultrasound should be offered. Minimum effective doses should be given and monitoring of plasma levels is recommended.

If pregnancy occurs in a woman receiving Teril, or if the question of initiating treatment with Teril arises during pregnancy, the drug's potential benefits must be carefully weighed against its possible hazards, particularly in the first three months of pregnancy.
In the neonate

In order to prevent bleeding disorder in the offspring, it has been recommended that vitamin K₁ (phytomenadione), be given to the mother during the last weeks of pregnancy as well as to the neonate.

There have been a few cases of neonatal seizures and/or respiratory depression associated with maternal Teril and other concomitant anticonvulsant drug use. A few cases of neonatal vomiting, diarrhea and/or decreased feeding have also been reported in association with maternal Teril use. These reactions may represent a neonatal withdrawal syndrome.

Use in Lactation

Carbamazepine passes into human milk (about 25 to 60% of plasma concentrations). The benefits of breastfeeding should be weighed against the remote possibility of adverse effects occurring in the infant. Mothers taking Teril may breastfeed their infants, provided the infant is observed for possible adverse reaction (e.g. excessive somnolence, allergic skin reaction).

INTERACTIONS WITH OTHER MEDICINES

Cytochrome P450 3A4 (CYP 3A4) is the main enzyme catalysing the formation of the active metabolite carbamazepine-10,11-epoxide. Co-administration of inhibitors of CYP 3A4 may result in an increased plasma concentration of carbamazepine which could induce adverse reactions. Co-administration of CYP 3A4 inducers might increase the rate of carbamazepine metabolism, thus leading to a decrease in carbamazepine plasma concentration and a potential decrease in the therapeutic effect. Similarly, discontinuation of a CYP 3A4 inducer may decrease the rate of metabolism of carbamazepine, leading to an increase in carbamazepine plasma levels.

Carbamazepine is a potent inducer of CYP3A4 and other phase I and II enzyme systems in the liver and may therefore reduce plasma concentrations of co-medications mainly metabolised by CYP3A4 by induction of their metabolism.

Human microsomal epoxide hydrolase has been identified as the enzyme responsible for the formation of the 10,11-transdiol derivative from carbamazepine-10,11 epoxide. Co-administration of inhibitors of human microsomal epoxide hydrolase may result in increased carbamazepine-10,11 epoxide plasma concentrations.

Agents that may raise carbamazepine plasma concentrations:

Since high plasma concentrations of carbamazepine may result in adverse reactions (e.g. dizziness, drowsiness, ataxia, diplopia), the dosage of Teril should be adjusted accordingly and/or the plasma concentrations monitored when used concomitantly with the substance described below.

Analgesics, anti-inflammatory drugs: dextropropoxyphene, ibuprofen.

Androgens: danazol.

Antibiotics: macrolide antibiotics (e.g. erythromycin, troleandomycin, josamycin, clarithromycin), ciprofloxacin.

Antidepressants: possibly desipramine, fluoxetine, fluvoxamine, nefazodone, paroxetine, trazodone.
Antiepileptics: vigabratin.

Antifungal: azoles (e.g. itraconazole, ketoconazole, fluconazole, voriconazole).

Antihistamines: loratadine, terfenadine.

Antipsychotics: olanzapine, quetiapine.

Antituberculosis: isoniazid.

Antivirals: protease inhibitors for HIV treatment (e.g. ritonavir).

Carbonic anhydrase inhibitors: acetazolamide

Cardiovascular drugs: diltiazem, verapramil.

Gastrointestinal drugs: possibly cimetidine, omeprazole.

Muscle relaxants: oxybutynin, dantrolene.

Platelet aggregation inhibitors: ticlopidine.

Other interactions: grapefruit juice, nicotinamide (in adults, only in high doses).

**Agents that may raise the active metabolite carbamazepine-10,11-epoxide plasma levels:**

Since raised plasma carbamazepine-10,11-epoxide levels may result in adverse reactions (e.g. dizziness, drowsiness, ataxia, diplopia), the dosage of Teril should be adjusted accordingly and/or the plasma levels monitored when used concomitantly with the substances described below:

- Quetiapine, valproic acid, valnoctamide, valpromide and primidone.

**Agents that may decrease carbamazepine plasma concentrations.**

The dose of Teril consequently may have to be adjusted when used concomitantly with the substances described below.

- Antiepileptics: oxcarbazepine, phenobarbitone, phenytoin, primidone, progabide, and, although the data are partly contradictory, possibly also by clonazepam, valproic acid, valpromide
- Antineoplasics: cisplatin, doxorubicin
- Antituberculosis: rifampicin
- Bronchodilators or anti-asthma drugs: theophylline, aminophylline
- Dermatological drugs: isotretnoin has been reported to alter the bioavailability and/or clearance of carbamazepine and carbamazepine-10,11-epoxide; carbamazepine plasma concentrations should be monitored.
- Other interactions: herbal preparations containing St John’s wort (*Hypericum perforatum*)
Effect of carbamazepine on plasma concentrations of concomitant drugs.

Due to the induction of the hepatic monooxygenase enzyme system, carbamazepine may lower the plasma concentration and diminish or even abolish the activity of certain drugs that are metabolised by this system. The dosage of the following drugs may have to be adjusted to clinical requirements:

Analgesics, anti-inflammatory agents: buprenorphine, methadone, paracetamol, tramadol.

Antibiotics: doxycycline.

Anticoagulants: oral anticoagulants (warfarin).

Antidepressants: bupropion, citalopram, mianserin, nefazodone, sertraline, trazodone, tricyclic antidepressants (e.g. imipramine, amitriptyline, nortriptyline, clomipramine).

Antiemetics: aprepitant.

Antiepileptics: clobazam, clonazepam, ethosuximide, lamotrigine, oxcarbazepine, primidone, tiagabine, topiramate, valproic acid. Plasma concentrations of phenytoin have been reported to be both raised and lowered by carbamazepine, and mephenytoin plasma levels have been reported in rare instances to increase.

Antifungals: itraconazole.

Antihelminitics: praziquantel, albendazole.

Antineoplastics: imatinib, cyclophosphamide, lapatinib, temsirolimus.

Antipsychotics: clozapine, haloperidol, bromperidol, olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, paliperidone.

Antivirals: protease inhibitors for HIV treatment (e.g. indinavir, ritonavir, saquinavir).

Anxiolytics: alprazolam, midazolam

Bronchodilators or anti-asthma drugs: theophylline.

Contraceptives: hormonal contraceptives (alternative contraceptive methods should be considered).

Cardiovascular drugs: digoxin, calcium channel blockers (dihydropyridine group) e.g. felodipine.

Corticosteroids: corticosteroids (e.g. prednisolone, dexamethasone).

Drugs used in erectile dysfunction: tadalafil.

Immunosuppressants: cyclosporine, everolimus, tacrolimus, sirolimus.

Thyroid agents: levothyroxine.

Other drug interactions: products containing oestrogens and/or progesterones

Combinations to be taken into consideration.

Concurrent use of carbamazepine and isoniazid has been reported to increase isoniazid induced hepatotoxicity.
Concomitant use of carbamazepine and levetiracetam has been reported to increase carbamazepine-induced toxicity.

Combined use of carbamazepine and lithium or metoclopramide on one hand and carbamazepine and major tranquillisers (haloperidol, thioridazine) on the other may lead to an increase in neurological adverse reactions (even in the presence of therapeutic plasma level concentrations with the latter combination).

Concurrent medication with Teril and some diuretics (hydrochlorothiazide, frusemide) may lead to symptomatic hyponatraemia.

Carbamazepine may antagonise the effects of nondepolarising muscle relaxants (e.g. pancuronium); their dosage may need to be raised and patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected.

Carbamazepine, like other psychoactive drugs, may reduce alcohol tolerance; it is therefore advisable for the patient to abstain from alcohol.

Teril should not be administered with monoamine oxidase inhibitors (MAOI).

Serotonin re-uptake inhibitors. The causative role of carbamazepine in inducing or contributing to the development of a serotonin syndrome during concomitant use with selective serotonin reuptake inhibitors is unclear. (Symptoms of serotonin syndrome include hyperthermia, tremor, convulsions, sweating, muscle contractions and changes in mental state, including confusion, irritability and extreme agitation).

ADVERSE EFFECTS

Particularly at the start of treatment with Teril, or if the initial dosage is too high, or when treating elderly patients, certain types of adverse reactions occur more frequently, e.g. CNS adverse reactions (dizziness, headache, ataxia, drowsiness, fatigue, diplopia), gastrointestinal disturbances (nausea, vomiting), as well as allergic skin reactions. Such reactions can be minimised by starting with a low dose.

The dose related adverse reactions usually abate within a few days, either spontaneously or after a dosage reduction. The occurrence of CNS adverse reactions may be a manifestation of relative overdosage or significant fluctuation in concentration of the drug in plasma. In such cases it is advisable to monitor the plasma concentrations and possibly to lower the daily dosage and/or divide it into 3 or 4 fractional doses.

Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (>1/10); common (>1/100, <1/10); uncommon (>1/1,000, <1/100); rare (>1/10,000, <1/1,000); very rare (<1/10,000), including isolated reports.

Nervous system disorders

Very common: dizziness, ataxia, drowsiness, fatigue.

Common: headache, diplopia, accommodation disorder (e.g. blurred vision), increases in seizure frequency in patients with atypical absences.
Uncommon: abnormal involuntary movements (e.g. tremor, asterixis, dystonia, tics), nystagmus.

Rare: orofacial dyskinesia, choreoathetosis, eye movement disturbances, speech disorders (e.g. dysarthria or slurred speech), neuropathy peripheral, paraesthesia, paresis. There have been some reports of paralysis and other symptoms of cerebral arterial insufficiency, but no conclusive relationship to the administration of carbamazepine could be established.

Very rare: taste disturbances, neuroleptic malignant syndrome (the causative role of carbamazepine in inducing or contributing to the development of neuroleptic malignant syndrome, especially in conjunction with neuroleptics, is unclear).

Psychiatric disorders

Rare: hallucinations (visual or auditory), depression, anorexia, restlessness, aggression, agitation, confusional state.

Very rare: activation of psychosis.

Skin and subcutaneous tissue disorders

Very common: dermatitis allergic, urticaria, which may be severe.

Uncommon: exfoliative dermatitis and erythroderma.

Rare: systemic lupus erythematosus, pruritus.

Very rare: Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity reaction, erythema multiforme and nodosum, alterations in skin pigmentation, purpura, acne, hyperhydrosis, hair loss and hirsutism.

Blood and lymphatic system disorders

Very common: leucopenia.

Common: eosinophilia, thrombocytopenia.

Rare: leucocytosis, lymphadenopathy, folic acid deficiency.

Very rare: agranulocytosis/aplastic anaemia (with fatal outcome in some cases), pancytopenia, pure red cell aplasia, anaemia, megaloblastic anaemia, acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda, reticulocytosis, and possibly haemolytic anaemia.

Hepato-biliary disorders

Very common: increased gamma-GT due to hepatic enzyme induction (usually not clinically relevant).

Common: increased blood alkaline phosphatase.

Uncommon: increased transaminases.

Rare: jaundice; cholestatic, parenchymal (hepatocellular) or mixed type hepatitis, vanishing bile duct syndrome.
Very rare: granulomatous hepatitis, hepatic failure.

Gastrointestinal disorders

Very common: nausea, vomiting.

Common: dry mouth.

Uncommon: diarrhoea, constipation.

Rare: abdominal pain.

Very rare: glossitis, stomatitis, pancreatitis.

Immune system disorders

Rare: a delayed multiorgan hypersensitivity disorder with fever, rashes, vasculitis, lymphadenopathy, pseudo lymphoma, arthralgia, leucopenia, eosinophilia, hepatosplenomegaly and abnormal liver function tests and vanishing bile duct syndrome (destruction and disappearance of the intrahepatic bile ducts), occurring in various combinations. Other organs may also be affected (e.g. lungs, kidneys, pancreas, myocardium, colon).

Very rare: aseptic meningitis, with myoclonus and peripheral eosinophilia; anaphylactic reactions, angioneurotic edema.

Cardiac disorders

Rare: cardiac conduction disorders, hypertension or hypotension.

Very rare: bradycardia, arrhythmias, Stokes-Adams attacks and syncope associated with atrioventricular block, circulatory collapse, congestive heart failure, aggravation of symptoms of coronary insufficiency, thrombophlebitis, thromboembolism (e.g. pulmonary embolism).

Endocrine disorders

Common: oedema, fluid retention, weight increase, hyponatraemia and blood osmolarity decreased due to an antidiuretic hormone (ADH)-like effect, leading in isolated cases to water intoxication accompanied by lethargy, vomiting, headache, confusional state, neurological disorders.

Very rare: blood prolactin increased with or without clinical manifestations such as galactorrhoea; gynaecomastia; abnormal thyroid function tests; decreased L-thyroxine (free thyroxine, thyroxine, tri iodothyronine) and increased blood thyroid stimulating hormone, usually without clinical manifestations; bone metabolism disorders (decrease in plasma calcium and blood 25-hydroxy-cholecalciferol), leading to osteomalacia/osteoporosis; increased blood cholesterol, including HDL cholesterol and triglycerides.

Renal and urinary disorders

Very rare: interstitial nephritis and renal failure, renal impairment (e.g. albuminuria, haematuria, oliguria and blood urea increased azotaemia), urinary frequency, urinary retention.
Reproductive system

*Very rare:* sexual dysfunction/impotence, spermatogenesis abnormal (with decreased sperm count and/or motility).

Eye disorders

*Very rare:* lenticular opacities (see PRECAUTIONS), conjunctivitis, intraocular pressure increased.

Ear and labyrinth disorders

*Very rare:* hearing disorders (e.g. tinnitus, hyperacusis, hypoacusis, change in pitch perception).

Musculoskeletal, connective tissue and bone disorders

*Rare:* muscular weakness

*Very rare:* arthralgia, muscle pain, muscle spasms.

Respiratory, thoracic and mediastinal disorders

*Very rare:* pulmonary hypersensitivity characterised by fever, dyspnoea, pneumonitis or pneumonia.

Investigations

*Very rare:* hypogammaglobulinaemia.

Adverse drug reactions from spontaneous reports and literature cases (frequency not known)

The following adverse drug reactions have been derived from post-marketing experience with carbamazepine via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.

Immune system disorders: Drug Rash with Eosinophilia and Systemic Symptoms (DRESS).

Skin and subcutaneous tissue disorders: Acute Generalised Exanthematous Pustulosis (AGEP).

**DOSAGE AND ADMINISTRATION**

The tablets may be taken during or after meals, or with a little fluid.

Women of childbearing age under treatment with Teril should be counselled to inform their medical practitioner immediately if pregnancy is suspected.

In elderly patients the dosage of Teril should be selected with caution.
Epilepsy

Wherever possible, Teril should be prescribed as monotherapy. Treatment should be initiated with a low daily dosage, to be slowly increased until an optimal effect is obtained. After obtaining adequate seizure control dosage may be reduced very gradually to minimum effect level.

Determination of plasma concentrations may help in establishing the optimum dosage (see PRECAUTIONS).

When Teril is added to existing anticonvulsant therapy, this should be done gradually while maintaining, or if necessary adjusting, the dosage of the other anticonvulsant(s) (see INTERACTIONS WITH OTHER MEDICINES).

Adults and children over 15 years. Initially 100 mg to 200 mg once or twice daily, gradually increasing the dosage until an optimum response is obtained (generally at 400 mg two or three times daily). In some patients 1,600 or even 2,000 mg daily may be required in rare instances.

Children. The initial dose for children 13 to 15 years is the same as for adults. The recommended maintenance dose for children 11 to 15 years is 600 to 1,000 mg daily. Daily dose should generally not exceed 1,000 mg.

In children 6 to 10 years the recommended maintenance dose is 400 to 600 mg daily.

Limited data are available concerning the safety and efficacy in children less than 6 years old.

Trigeminal neuralgia

The recommended initial dose is 200 to 400 mg daily in two divided doses increasing by 200 mg each day in divided doses until pain relief is obtained. This is usually achieved with doses up to 800 mg daily. Larger doses should be given as three to four divided doses. The maximum dose should not exceed 1,200 mg daily. As soon as the pain is well controlled, gradually reduce the dosage to the minimal effective level. Because trigeminal neuralgia is characterised by periods of remission, attempts should be made to reduce or discontinue the use of carbamazepine at intervals of not more than three months.

Mania and maintenance treatment of bipolar affective disorder

The dosage range is 400 to 1,600 mg daily. When used alone in mania, the starting dose of carbamazepine should be 200 to 400 mg daily in two divided doses. Dosage should be increased to 800 to 1,000 mg during the first week by daily increments of 200 mg and up to 1,600 mg if no response is found after a second week.

For maintenance treatment, carbamazepine is commenced at a dosage of 200 to 400 mg daily in two divided doses. Dosage should be increased weekly by increments of 100 mg. Due to autoinduction, concentrations may fall after two to three weeks and dosage increases may be necessary after this time. The same plasma level range as for anticonvulsant therapy is considered adequate (4 to 12 microgram/mL; 17 to 50 micromol/L), however dose increases should be titrated against the appearance of side effects.
OVERDOSAGE

Signs and symptoms

The presenting signs and symptoms of overdosage develop within one to three hours of ingestion and usually involve the central nervous, cardiovascular and respiratory systems. Relapse and aggravation of symptoms on the second and third days after overdose may occur. This is thought to be due to delayed absorption, possibly due to production of a gastric mass of tablets.

Central nervous system. CNS depression, disorientation, somnolence, agitation, hallucination, coma, blurred vision, slurred speech, dysarthria, nystagmus, ataxia, dyskinesia, initially hyperreflexia, later hyporeflexia, convulsion (especially in small children), psychomotor disturbances, myoclonus, hypothermia, mydriasis.

Respiratory. Respiratory depression, pulmonary oedema.

Cardiovascular. Tachycardia, hypotension, at times hypertension, conduction disturbance with widening of QRS complex, syncope in association with cardiac arrest.

Gastrointestinal. Vomiting, delayed gastric emptying, reduced bowel motility.

Renal. Retention of urine, oliguria or anuria; fluid retention, water intoxication due to an antidiuretic hormone-like effect of carbamazepine.

Laboratory findings. Hyponatraemia (see Management), leucocytosis, leucopenia, hypokalaemia, metabolic acidosis, hyperglycaemia, glycosuria, acetonuria, increased muscle creatien phosphokinase.

Management

There is no specific antidote. Management should be guided initially by the patient's clinical condition. All patients suspected of serious overdose should be admitted to hospital and the plasma carbamazepine concentration measured to confirm carbamazepine poisoning and to ascertain the size of the overdose.

Administer activated charcoal. If the patient's level of consciousness is impaired, intubation may be necessary to protect the airway. Supportive medical care in an intensive care unit with cardiac monitoring and careful correction of electrolyte imbalance.

Hyponatraemia is not usually a problem in acute overdosage. However, in chronic intoxication it may be managed by fluid restriction and slow and careful intravenous infusion of sodium chloride 0.9%. These measures may be useful in preventing brain damage.

Special recommendations

Hypotension: intravenous fluid replacement. If the patient fails to respond, consider intravenous dopamine or dobutamine.

Disturbances of cardiac rhythm. There are no data regarding drug treatment of carbamazepine induced arrhythmias. These should, therefore, be handled according to the circumstances in each patient.
Convulsion: Initially, administer a benzodiazepine (e.g. diazepam) if seizures occur. If seizures recur, another anticonvulsant, e.g. phenobarbitone (with caution because of increased respiratory depression) may be considered.

Charcoal haemoperfusion has been recommended. Forced diuresis, haemodialysis, and peritoneal dialysis have been reported to be not effective.

The Poisons Information Centre (131126) should be contacted for further advice on treatment and management.

PRESENTATION AND STORAGE CONDITIONS

**Teril**, 200 mg tablet: white, uncoated, marked CB on one side and G on the reverse; 200’s.

Store below 30°C.

POISON SCHEDULE OF THE MEDICINE

S4 – Prescription Only Medicine

NAME AND ADDRESS OF THE SPONSOR

Alphapharm Pty Limited

Level 1, 30 The Bond

30 – 34 Hickson Road

Millers Point NSW 2000

ABN 002 359 739

www.alphapharm.com.au

DATE OF APPROVAL

Approved by the Therapeutic Goods Administration on 8 August 2000.

Date of most recent amendment: 19 January 2012.